Subcutaneous Daratumumab (DARA SC) with Standard-ofCare (SoC) in Multiple Myeloma (MM) across therapy lines in phase 2 PLEIADES: Initial results with SoC Carfilzomib/Dexamethasone (D-Kd) and updated results with SoC Bortezomib/Melphalan/Prednisone (D-VMP) or Lenalidomide/Dexamethasone (D-Rd)

Authors :: Goldschmidt, H
Chari, A
Haenel, M
Oriol, A
Rodriguez-Otero, P
McCarthy, H
Suzuki, K
Hungria, V
Balari, AS
Clement-Filliatre, L
Hulin, C
Magen, H
Iida, S
Maisnar, V
Karlin, L
Pour, L
Touzeau, C
Yang, S
Kosh, M
Delioukina, M
Heuck, C
Moreau, P
Source :: Oncology Research and Treatment, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Publication Year :: 2021
Publisher :: S. Karger AG, 2021.

ISSN :: 22965262
Database :: OpenAIRE
Journal :: Oncology Research and Treatment, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Accession number :: edsair.RECOLECTA.....d883d9478f1b14c7c46ba78833f9f313

Tools